» Articles » PMID: 23097701

Usefulness of Patients-reported Outcomes in Rheumatoid Arthritis Focus Group

Abstract

Objective. Patient-reported outcomes (PROs) have become an essential part of the assessment of patients with rheumatoid arthritis (RA). We aimed to evaluate the agreement and correlation between PROs and the physician's measurements. Methods. This was a cross-sectional analytical study in which 135 patients with RA were clinically evaluated during two different sessions of focus group interviews. Rheumatologist recorded 28 swollen (SJCs) and tender joint counts (TJCs). The patients filled out the PROs instruments (MDHAQ, RADAI, RAPID3, 4, and 5 and self-report articular index (SAI) diagram for pain and joint swelling). DAS28 was calculated (C-reactive protein). An adjusted multiple lineal regression model was done (DAS28 as dependent variable). Results. Highly significant agreements were found between SJC and TJC registered by the physician and patient. There was moderate correlation between DAS28 with patient SJC (r = 0.52), patient TJC (r = 0.55), RADAI (r = 0.56), RAPID3 (r = 0.52), RAPID4 (r = 0.56), RAPID5 (r = 0.66), and VAS-Global (r = 0.51). Likewise, we found moderate to high correlations between CDAI and SDAI with all variable measurements done by the patients. The resulting predictive equation was DAS28(CRP) = 2.02 + 0.037 × RAPID4 + 0.042× patient SJC. Conclusion. PROs applied in focus groups interview are a useful tool for managing patients with RA regardless of gender, educational level, and duration of disease.

Citing Articles

In silico identification of compounds from Roxb leaf fractionated extract inhibit interleukin-6 to prevent rheumatoid arthritis.

Dao T, Onikanni S, Fadaka A, Klein A, De Tran V, Le M Front Pharmacol. 2024; 15:1358037.

PMID: 38576490 PMC: 10991700. DOI: 10.3389/fphar.2024.1358037.


L. Extract (Saffron) Effectively Reduces Arthritic and Inflammatory Parameters in Monotherapy and in Combination with Methotrexate in Adjuvant Arthritis.

Chrastina M, Drafi F, Pruzinska K, Ponist S, Kamga K, Khademnematolahi S Nutrients. 2023; 15(19).

PMID: 37836391 PMC: 10574733. DOI: 10.3390/nu15194108.


Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe.

Mousavi M, Karami J, Aslani S, Tahmasebi M, Vaziri A, Jamshidi A Auto Immun Highlights. 2021; 12(1):3.

PMID: 33546769 PMC: 7863458. DOI: 10.1186/s13317-020-00145-x.


Investigational treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear.

Addorisio M, Imperato G, de Vos A, Forti S, Goldstein R, Pavlov V Bioelectron Med. 2020; 5:4.

PMID: 32232095 PMC: 7098240. DOI: 10.1186/s42234-019-0020-4.


Nonsurgical management of temporomandibular joint autoimmune disorders.

Shoohanizad E, Garajei A, Enamzadeh A, Yari A AIMS Public Health. 2020; 6(4):554-567.

PMID: 31909075 PMC: 6940567. DOI: 10.3934/publichealth.2019.4.554.


References
1.
Pincus T . Pain, function, and RAPID scores: vital signs in chronic diseases, analogous to pulse and temperature in acute diseases and blood pressure and cholesterol in long-term health. Bull NYU Hosp Jt Dis. 2008; 66(2):155-65. View

2.
Kvien T, Uhlig T, Odegard S, Heiberg M . Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci. 2006; 1069:212-22. DOI: 10.1196/annals.1351.019. View

3.
Fiscella K, Ransom S, Jean-Pierre P, Cella D, Stein K, Bauer J . Patient-reported outcome measures suitable to assessment of patient navigation. Cancer. 2011; 117(15 Suppl):3603-17. PMC: 4407470. DOI: 10.1002/cncr.26260. View

4.
Werner C A, Kaliski K S, Salazar Q K, Bustos M L, Rojas R M, Baumert L C . [Knowledge about their disease and treatment among patients with rheumatoid arthritis]. Rev Med Chil. 2007; 134(12):1500-6. DOI: 10.4067/s0034-98872006001200002. View

5.
Wolfe F, Michaud K . Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol. 2008; 36(1):27-33. DOI: 10.3899/jrheum.080591. View